13 completed, 2 terminated, 2 withdrawn. 9 Phase 2, 8 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 2, Withdrawn 1 |
| Phase 1 | 8 | Completed 5, Withdrawn 2, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow Recurrent Primary Peritoneal Cavity Cancer: new trials by email Literature Review of Recurrent Primary Peritoneal Cavity Cancer trials Research Report on Recurrent Primary Peritoneal Cavity Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 | |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer mifepristone, carboplatin, gemcitabine hydrochloride - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Chicago | 31 | 2013-11-01 | 2018-09-11 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer paclitaxel, ganetespib, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 12 | 2013-10-09 | 2024-03-26 |
| Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer auranofin, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Early Phase 1 | Completed | Mayo Clinic | 10 | 2012-11-02 | 2019-08-02 |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 7 | 2012-08-20 | 2020-03-27 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride - Leydig Cell Tumor, Ovarian Sarcoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 12 | 2012-05-01 | 2015-08-04 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer questionnaire administration, quality-of-life assessment, psychosocial assessment and care - Anxiety Disorder, Depression | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 39 | 2010-10-01 | 2015-10-09 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin SJG-136, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 19 | 2010-07-01 | 2015-05-25 |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2009-04-01 | 2022-08-01 |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer sunitinib malate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2007-01-01 | 2015-01-27 |
| AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery AFP464, pharmacological study, laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 68 | 2006-07-01 | 2014-02-24 |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer cediranib maleate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2006-04-01 | 2018-08-29 |
| Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer gemcitabine hydrochloride, sorafenib tosylate, laboratory biomarker analysis - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2004-09-01 | 2013-06-13 |
| Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer cisplatin, alvocidib, cisplatin/flavopiridol - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2004-04-01 | 2014-05-21 |
| Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer fenretinide, laboratory biomarker analysis, pharmacological study - Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2001-09-01 | 2013-03-25 |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, carboplatin, paclitaxel - Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2019-02-20 |
Carcinoma, Ovarian Epithelial (17) · Fallopian Tube Neoplasms (13) · Breast Neoplasms (3) · Breast Neoplasms, Male (2) · Endometrial Neoplasms (2) · Leydig Cell Tumor (2) · Pseudomyxoma Peritonei (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Anxiety Disorders (1) · Brenner Tumor (1) · Carcinoma, Renal Cell (1) · Depression (1) · Fatigue (1)
Adnexal Diseases (17) · Carcinoma (17) · Endocrine Gland Neoplasms (17) · Endocrine System Diseases (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Genital Diseases (17) · Genital Diseases, Female (17) · Genital Neoplasms, Female (17) · Gonadal Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Ovarian Diseases (17)
Carboplatin (3) · Gemcitabine (3) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Metformin (2) · Paclitaxel (2) · Taxes (2) · sargramostim (2) · 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · Auranofin (1) · Behavior Therapy (1) · Chromatography, Liquid (1) · Cisplatin (1) · DNA Methylation (1) · Decitabine (1) · Drug Therapy (1)
National Cancer Institute (NCI) (7) · Roswell Park Cancer Institute (3) · Fox Chase Cancer Center (2) · University of Chicago (2) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1)
United States (14) · Canada (3)
Kunle Odunsi (3) · Agustin Garcia (1) · Aminah Jatoi, M.D. (1) · Amit Oza (1) · Angela Jain (1) · Barbara Andersen, PhD (1) · Gina Martina-Smaldone, MD (1) · Holger Hirte (1) · James Biagi (1) · Keith Bible (1) · Marta Crispens (1) · Matthew Goetz (1) · Rita Nanda (1) · Seiko Yamada (1) · Steven Waggoner, MD (1)
PMID 22664059, PMID 25895616, PMID 35254001, PMID 40132910
N01CM62203 (2), P30CA006927 (2), P30CA015083 (2), N01CM00100 (1), N01CM17101 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA014599 (1), P30CA016056 (1), R21CA135005 (1), U01CA069912 (1)